A 64-year-old man seeking treatment for a common cold was admitted to our hospital due to symptoms of general fatigue and liver dysfunction. A thorough history review revealed that the patient had recently started taking an over-the-counter (OTC) drug. Drug-induced lymphocyte stimulation tests were positive. Serum markers for autoimmune hepatitis (AIH) were particularly elevated. Liver biopsy revealed spotty necrosis and ceroid-pigmented Kupffer cells and piecemeal necrosis with multiple plasma cells. He responded to corticosteroids, thus suggesting the presence of an immune-mediated component associated with the liver injury. Liver injury after using OTCs should be included in the differential diagnosis for chronic hepatitis with features of AIH.
Introduction
Drug-induced liver injury (DILI) is being increasingly recognized as a cause of clinically significant acute and chronic liver disease. Marked geographic variation exists among the agents responsible for causing DILI (1) . In fact, DILI is associated with certain over-the-counter (OTC) drugs, prescription drugs, and dietary supplements, many of which make bold promises about improving symptoms and bolstering health (2) . A popular Japanese cold medicine Pabron Gold (Taisho Pharma, Tokyo, Japan) can be purchased at pharmacies in Japan, Thailand, Malaysia, and Chinese Taipei as a multi-component cold medicine.
Autoimmune hepatitis (AIH) is pathologically characterized by chronic necro-inflammation, manifested as severe lobular necrosis and inflammation with broad areas of parenchymal collapse with no known cause. The etiology of AIH remains uncertain, but external factors such as viruses, drugs, or herbal remedies can sometimes trigger this disease in susceptible persons (3) . Recently, drug-induced AIH (DI-AIH) has come to account for a sizable share, approximately 9%, of all AIH cases (4). This report is the first to describe a patient who developed DI-AIH following the use of an OTC drug. This case is characterized by cholestasis and the histologic features of AIH which improved after the administration of corticosteroid therapy.
Case Report
A 64-year-old man seeking treatment for a common cold was admitted to our hospital for general fatigue and liver dysfunction. He had not reported any liver dysfunction. Blood test results included data for total bilirubin (T-bil) 2.4 mg/dL; direct bilirubin (D-bil) 1.4 mg/dL; aspartate aminotransferase (AST) 1,244 IU/L; alanine aminotransferase (ALT) 1,455 IU/L; alkaline phosphatase (ALP) 1,242 IU/L; and γ-glutamyl transpeptidase (γ-GTP) 599 IU/L. Viral hepatitis serology was negative. Other relevant data included an immunoglobulin (Ig) G concentration of 1,907 mg/dL, IgM of 95 mg/dL, anti-nuclear antibody (ANA) ×80 (cut-off < ×40), anti-smooth muscle antibody (ASMA) ×20 (cut-off < ×20), negative liver kidney microsomal type 1 (LKM-1) (cut-off <5.0), and negative mitochondria M2Ab (cut-off <5.0) (Table) . Computed tomography revealed no sign of any mass lesions ( Fig. 1a ). Magnetic resonance cholangiopancreatography revealed no stones or extrahepatic biliary duct dilatation ( Fig. 1b) months. Thereafter, he started to develop persistent epigastric distress and general malaise. His symptoms worsened whenever he took that medication. He was referred to our hospital two days after the last dose. After one month of Pabron Gold treatment, the patient started to develop persistent general malaise. The cause was suspected to be liver injury. A DI lymphocyte stimulation test for Pabron Gold was positive: 2,447 cpm (503%) (<179%). A needle liver biopsy was performed on admission day 3, the results of which revealed spotty necrosis and ceroid-pigmented Kupffer cells around the central vein ( Fig. 2a and b ) and interface hepatitis with multiple plasma cells around the portal tracts ( Fig. 2a, c, d) . Plasmocytic infiltration showed positive CD79a staining with negative CD20 staining ( Fig. 2e and f) . These infiltrated cells were found to be plasma cells by immunohistochemistry. Ultrastructurally, a "cart-wheel" chromatin configuration in the nucleus was observed in some plasma cells packed with many roughsurfaced endoplasmic reticulum ( Fig. 3a and b) . Moreover, characteristic granular osmiophilic materials and lipid droplets were observed in the Kupffer cells ( Fig. 3c and d) . The human leukocyte antigen (HLA) typing test was HLA-DRB *1-0405 (DR4) positive. The use of Pabron Gold was strongly suspected as being responsible for the patient's condition. The DI hepatitis score (5) was 8, AIH diagnosis (6) was 6: probable. Liver function improvement was noted after administering a liver protection agent: glycyrrhetinic acid. He showed a persistent rise in the transaminase concentrations at around day 30. Therefore, steroids with prednisolone were prescribed at a dose of 40 mg/day to control the hepatic inflammation contributing to the hepatocellular injury. The transaminase levels began to decline after the administration of prednisolone for 3 days. They thereafter normalized by the end of two weeks (Fig. 4 ).
Discussion
This report is the first to describe a case of DI-AIH following the use of an OTC drug. In fact, a DI-AIH diagnosis presents a challenge to clinicians because neither the histological nor clinical pathognomonic features of AIH have yet been elucidated. Moreover, HLA haplotypes do not convincingly distinguish these two entities (4) . It is practically impossible to exclude potential drug involvement in some cases. Therefore, making a differential diagnosis of idiopathic AIH or DI-AIH can be extremely difficult. Clinically, DI-AIH commonly has an acute onset and a low frequency of cirrhosis at presentation and during follow-up (4) .
In all, 14% of such cases exhibit clinically severe hepato-cellular injury and jaundice on either initial or rechallenge events. Most patients (52%) undergo drug rechallenge within a month following the initial liver injury event (7) . During follow-up, regarding transferases with the liver protection agent, our patient showed a persistent increase in the transaminase levels, elevated immunoglobulin levels, and ASMA values, which were monitored in spite of plasma cell infiltration observed from liver histology because of the inferred DI-AIH related liver damage (8) . Suspecting DI-AIH, in accordance with the data and recommendations reported to date and because treatment should be initiated as soon as possible, we initiated prednisolone treatment at an early stage (4) .
Liver biopsy revealed the prominence of ceroid pigment within Kupffer cells in the centrilobular areas. The laboratory data and liver biopsy findings suggested hepatitis with cholestatic features (9) . Kupffer cells are highly phagocytic members of the mononuclear phagocyte family. In response to hepatocyte damage from OTC intake, they can proliferate and enlarge, often amassing a so-called ceroid pigment, a material that chemically resembles lipofuscin, which is derived from phagocytosed cellular debris (10) . Ceroid pig- ments are apparent in acute viral hepatitis, acute AIH, and an acute exacerbation of AIH other than DILI. Therefore, this finding is not pathognomonic for DILI. Rather, it shows the presence of acute hepatocellular injury (11) . Consequently, it is difficult to differentiate DIHI acute AIH, or an acute exacerbation of AIH using histology alone.
In this case, the plasmocytic cells in the periportal areas were positive for CD79a, but they were negative for CD20 ( Fig. 3e and f) . In fact, these results resembled the previously reported results in the literature (12) . Numerous plasma cells infiltrating the periportal area were observed from liver histology. In conclusion, this case of OTC drug Pabron Gold -associated liver injury, diagnosed as DI-AIH, underscores the need for caution in the use of OTC drugs.
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